KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine

Corey Casper, Lawrence Corey, Jeffrey I. Cohen, Blossom Damania, Anne A. Gershon, David C. Kaslow, Laurie T. Krug, Jeffrey Martin, Sam M. Mbulaiteye, Edward S. Mocarski, Patrick S. Moore, Javier Gordon Ogembo, Warren Phipps, Denise Whitby, Charles Wood

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop’s findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.

Original languageEnglish (US)
Article number108
Journalnpj Vaccines
Issue number1
StatePublished - Dec 2022
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine'. Together they form a unique fingerprint.

Cite this